JSPR · Jasper Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $9.76M | - | $9.35M | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.81M | - | $14.39M | $21.20M | $16.16M | - | $14.46M | $11.30M | $10.30M | - |
| SG&A | $5.14M | - | $4.78M | $5.88M | $5.64M | - | $5.43M | $4.70M | $4.77M | - |
| Total Operating Expenses | $10.95M | - | $19.17M | $27.08M | $21.80M | - | $19.89M | $15.99M | $15.07M | - |
| D&A | $21.0K | - | - | - | $279.0K | - | $300.0K | $300.0K | $288.0K | - |
| Operating Income | ($10.95M) | - | ($19.17M) | ($27.08M) | ($21.80M) | - | ($19.89M) | ($15.99M) | ($15.07M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.17M) | - | ($18.74M) | ($26.72M) | ($21.24M) | - | ($18.64M) | ($14.58M) | ($13.73M) | - |
| EPS - Basic | ($0.04) | - | ($1.13) | ($1.74) | ($1.41) | - | ($1.24) | ($0.97) | ($1.03) | - |
| EPS - Diluted | ($0.04) | - | ($1.13) | ($1.74) | ($1.41) | - | ($1.24) | ($0.97) | ($1.03) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.14M | $28.69M | $50.90M | $39.51M | $48.80M | $71.64M | $92.50M | $106.82M | $118.47M | $86.89M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.44M | $6.22M | $9.17M | $8.03M | $3.00M | $4.03M | $3.09M | $2.96M | $2.39M | $4.15M |
| Current Assets | $20.29M | $34.65M | $54.56M | $42.97M | $53.17M | $75.81M | $94.81M | $108.68M | $120.31M | $88.94M |
| Total Assets | $21.18M | $35.78M | $57.47M | $46.47M | $57.60M | $79.90M | $99.41M | $113.93M | $125.96M | $94.89M |
| Current Liabilities | $9.00M | $13.20M | $21.04M | $20.50M | $12.33M | $15.24M | $12.46M | $10.07M | $8.92M | $12.37M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $17.78M | $31.63M | $45.90M | $22.96M | $15.35M | $18.23M | $15.73M | $13.62M | $12.73M | $16.45M |
| Stockholders' Equity | $3.40M | $4.15M | $11.57M | $23.50M | $42.24M | $61.67M | $83.68M | $100.31M | $113.23M | $78.44M |
| Retained Earnings | ($317.84M) | ($316.67M) | ($307.57M) | ($288.83M) | ($262.11M) | ($240.87M) | ($216.55M) | ($197.91M) | ($183.33M) | ($169.60M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($14.55M) | - | - | - | ($22.84M) | - | - | - | ($15.74M) | - |
| Investing Cash Flow | - | - | - | - | $4.0K | - | - | - | ($25.0K) | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | $47.35M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.5% | - | -32.6% | -57.5% | -36.9% | - | -18.7% | -12.8% | -10.9% | - |
| Return on equity | -34.5% | - | -161.9% | -113.7% | -50.3% | - | -22.3% | -14.5% | -12.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.26 | 2.62 | 2.59 | 2.10 | 4.31 | 4.98 | 7.61 | 10.79 | 13.49 | 7.19 |
| Quick ratio | 2.26 | 2.62 | 2.59 | 2.10 | 4.31 | 4.98 | 7.61 | 10.79 | 13.49 | 7.19 |
| Cash ratio | 1.57 | 2.17 | 2.42 | 1.93 | 3.96 | 4.70 | 7.42 | 10.61 | 13.29 | 7.02 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 6.23 | 8.62 | 4.97 | 1.98 | 1.36 | 1.30 | 1.19 | 1.14 | 1.11 | 1.21 |
| Liabilities / Assets | 0.84 | 0.88 | 0.80 | 0.49 | 0.27 | 0.23 | 0.16 | 0.12 | 0.10 | 0.17 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 91d | - | 358d | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 7.4x | - | 3.4x | 3.6x | 1.5x | - | 3.4x | 3.4x | 3.5x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 49.8% | - | 3.6% | -69.3% | -44.7% | - | -2.7% | 10.3% | -8.1% | - |
| Net income growth (YoY) | 94.5% | - | -0.5% | -83.2% | -54.7% | - | -6.2% | 9.3% | 3.7% | - |
| EPS growth (YoY) | 97.2% | - | 8.9% | -79.4% | -36.9% | - | -675.0% | -234.5% | -543.8% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -92.0% | -93.3% | -86.2% | -76.6% | -62.7% | -21.4% | -11.1% | -9.0% | -9.6% | 118.0% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Jasper Therapeutics against the 5 most active filers in the same SIC group.